<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140303" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuroendocrine Tumor Lu-177-Dotatate Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Paluri</surname>
            <given-names>Ravi K.</given-names>
          </name>
          <aff>University of Alabama at Birmingham</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Killeen</surname>
            <given-names>Robert B.</given-names>
          </name>
          <aff>University of Illinois</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ravi Paluri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Killeen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140303.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Lutetium-177 (<sup>177</sup>Lu)-dotatate is a treatment modality used to manage and treat neuroendocrine tumor patients. Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies characterized by various presentations associated with indolent biological behavior. These tumors arise from neuroendocrine cells that are distributed in several areas of the body.&#x000a0;Lutetium-177 (<sup>177</sup>Lu)-dotatate therapy&#x000a0;or peptide receptor radioligand therapy (PRRT) is indicated for treating gastroenteropancreatic neuroendocrine tumors and&#x000a0;NET of the prostate gland.&#x000a0;The FDA approved&#x000a0;<sup>177</sup>Lu-dotatate therapy in 2018 to treat somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Most NETs show relatively high expression levels of SSTRs, which allows imaging and therapy using radiolabeled somatostatin analogs.&#x000a0;<sup>177</sup>Lu is a commonly used radionucleotide for targeted radiation therapy. The combination of radionucleotide&#x000a0;<sup>177</sup>Lu with somatostatin analog&#x000a0;dotatate delivers ionizing radiation targeting tumor cells that express somatostatin receptors, causing radiation-induced single and double-stranded DNA breaks leading to apoptosis. This activity reviews the indications, action, and contraindications for &#x000a0;<sup>177</sup>Lu-dotatate therapy as a valuable agent in the management of neuroendocrine or carcinoid tumors. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for members of the interprofessional, multidisciplinary teams involved in managing patients with advanced neuroendocrine tumors.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify disease-state information about neuroendocrine tumors and carcinoid syndrome.</p></list-item><list-item><p>Implement <sup>177</sup>Lu-dotatate therapy to improve overall survival and progression-free survival in adults with unresectable, advanced, or well or moderately-differentiated neuroendocrine tumors.</p></list-item><list-item><p>Evaluate the safety and efficacy of&#x000a0;<sup>177</sup>Lu-dotatate therapy for treating neuroendocrine tumors in adults.</p></list-item><list-item><p>Collaborate with the interprofessional team to educate, treat, and monitor patients with&#x000a0;<sup>177</sup>Lu-dotatate-treated neuroendocrine tumors&#x000a0;to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140303&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140303">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140303.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies characterized by various presentations associated with indolent biological behavior. These tumors arise from neuroendocrine cells that are distributed in several areas of the body. Lutetium-177 (<sup>177</sup>Lu)-dotatate therapy or peptide receptor radioligand therapy (PRRT) is indicated for treating gastroenteropancreatic neuroendocrine tumors and&#x000a0;NET of the prostate gland.&#x000a0;</p>
        <p>NETs account for &#x0003c;1% of all malignancies and comprise a diverse family throughout the endocrine system, including the gastrointestinal tract, bronchi, thymus, and adrenal glands. The most common locations are carcinoid gastrointestinal and pancreatic neuroendocrine tumors. These are&#x000a0;classified based on the degree of differentiation into well, moderately, or poorly differentiated tumors. Well-differentiated NETs arising within the digestive system are referred to as carcinoids. Gastrointestinal&#x000a0;neuroendocrine tumors (GINETS) and pancreatic NETs (PNETs) may have similar characteristics&#x000a0;by histology but have variable&#x000a0;clinical behavior and biology.<xref ref-type="bibr" rid="article-140303.r1">[1]</xref>&#x000a0;</p>
        <p>Pancreatic NETs have a relatively worse prognosis than GINETs&#x000a0;and respond differently to therapies, with most agents demonstrating somewhat higher responses with PNETs than those with GINETs.<xref ref-type="bibr" rid="article-140303.r2">[2]</xref> The most common site of metastasis is the liver.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth/abstract/6">6</ext-link>] Management is often dependent on the resectability of the tumor. Patients presenting with resectable or early-stage cancer have excellent clinical outcomes and control of symptoms. However,&#x000a0;with unresectable disease, the initial treatment is somatostatin analogs&#x000a0;such as octreotide or lanreotide to control the symptoms and tumor growth.</p>
        <p>Patients with symptomatic disease&#x000a0;are often treated initially with somatostatin analogs that are highly effective in controlling the symptoms of carcinoid syndrome but also control tumor growth. Treatment decisions are based on the patient's clinical presentation with hormonal symptoms and the type of treatment received before disease progression. NET patients need staging evaluation with Gallium-68 (<sup>68</sup>Ga)&#x000a0;dotatate or&#x000a0;Indium<sup>111</sup>&#x000a0;pentetreotide imaging to assess the expression of somatostatin receptors. Recently,&#x000a0;<sup>68</sup>Ga-dotatate imaging has supplanted Indium<sup>111</sup>&#x000a0;pentetreotide (ie, Octreoscan) imaging based on the availability of PET imaging.&#x000a0;Copper<sup>64&#x000a0;</sup>(Cu<sup>64</sup>) is a PET isotope similar to <sup>68</sup>Ga&#x000a0;that can be produced&#x000a0;in quantities to meet the clinical needs of imaging&#x000a0;centers without the supply&#x000a0;shortages of nuclear-generator-based positron emission tomography (PET) isotopes. Cu<sup>64</sup>-dotatate&#x000a0;has advantages over <sup>68</sup>Ga-dotatate in detecting significantly more NET lesions than <sup>68</sup>Ga-dotatate. The shelf life of Cu<sup>64</sup>&#x000a0;is over 24 hours, and the scanning window of at least 3 hours makes Cu<sup>64</sup>-dotatate logistically more favorable to use in the outpatient clinical setting.<xref ref-type="bibr" rid="article-140303.r3">[3]</xref>&#x000a0;A subset of patients with clinical or radiological progression after somatostatin analogs&#x000a0;are&#x000a0;managed with debulking palliative surgery, liver-directed interventions such as chemoembolization, or systemic radiolabeled somatostatin analogs such as <sup>177</sup>Lu-dotatate.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth/abstract/7">7</ext-link>]<xref ref-type="bibr" rid="article-140303.r4">[4]</xref>&#x000a0;Most clinical studies reporting efficacy with radiolabeled somatostatin analogs have included PNETs and GINETs.<xref ref-type="bibr" rid="article-140303.r5">[5]</xref>&#x000a0;</p>
        <p><sup>177</sup>Lu-dotatate also has efficacy in treating NET in other nonendocrine organs, such as the prostate.<xref ref-type="bibr" rid="article-140303.r6">[6]</xref>&#x000a0;When prostate cancer has progressed to an androgen-resistant state, one such result is neuroendocrine prostate cancer (NEPC).<xref ref-type="bibr" rid="article-140303.r7">[7]</xref>&#x000a0;This is due to the amplification of the <italic toggle="yes">NMYC</italic> and <italic toggle="yes">AURKA</italic> genes at the genetic level. NEPC is a highly aggressive variant with more frequent distant metastases, the development of drug resistance, more frequent loss of <italic toggle="yes">RB1</italic> and <italic toggle="yes">TP53</italic> genes, and patient death within a year. Studies have demonstrated a response to <sup>177</sup>Lu-dotatate with this tumor.<xref ref-type="bibr" rid="article-140303.r8">[8]</xref><xref ref-type="bibr" rid="article-140303.r9">[9]</xref><xref ref-type="bibr" rid="article-140303.r10">[10]</xref>&#x000a0;Despite dose-related renal toxicity, <sup>177</sup>Lu-dotatate is deemed safe and effective in NEPC.</p>
      </sec>
      <sec id="article-140303.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p><sup>177</sup>Lu-dotatate therapy is a form of endo-radiotherapy&#x000a0;that combines a radionuclide with a peptide that specifically binds to peptide receptors. The high affinity to these somatostatin receptors (SSTR) causes internalization of the receptor&#x02013;peptide complex by endocytosis. These peptide receptors (ie, somatostatin receptors) are expressed to a high concentration on tumor cells&#x000a0;as assessed by Gallium-68&#x000a0;PET scans.<xref ref-type="bibr" rid="article-140303.r11">[11]</xref>&#x000a0;</p>
        <p>The FDA approved <sup>177</sup>Lu-dotatate therapy in 2018 to treat somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Most NETs show relatively high expression levels of SSTRs, which allows imaging and therapy using radiolabeled somatostatin analogs. <sup>177</sup>Lu is a commonly used radionucleotide for targeted radiation therapy. The combination of radionucleotide <sup>177</sup>Lu with somatostatin analog dotatate delivers ionizing radiation targeting tumor cells that express somatostatin receptors, causing radiation-induced single and double-stranded DNA breaks leading to apoptosis. This action is more specific for somatostatin receptor-positive lesions.<xref ref-type="bibr" rid="article-140303.r12">[12]</xref>&#x000a0;Based on recent clinical studies, this treatment yielded a significant response rate with significant contributory symptomatic treatment.<xref ref-type="bibr" rid="article-140303.r13">[13]</xref> However, long-term effects include renal dysfunction, pancytopenia, and myelodysplastic syndrome. This treatment is commonly indicated for well-differentiated tumors with relatively high somatostatin receptor expression. <sup>177</sup>Lu-dotatate is the treatment of choice for&#x000a0;well-differentiated&#x000a0;neuroendocrine tumors, especially those who progress despite using long-acting somatostatin analogs. This treatment is favored over monitoring or administering targeted therapies such as everolimus or sunitinib.</p>
        <p><sup>177</sup>Lu-dotatate is administered as an intravenous infusion in an outpatient setting. The recommended dose is 7.4 GBq (200 mCi) every 8 weeks for 4 doses. Dose adjustments may be needed based on patients' renal and hematological parameters. Long-acting somatostatin analogs&#x000a0;will be discontinued for at least 4 weeks before initiating this therapy. However, short-acting octreotide is prescribed as needed for symptom control. After treatment, long-acting somatostatin analogs are continued every 4 weeks until the disease progresses.<xref ref-type="bibr" rid="article-140303.r14">[14]</xref></p>
        <p>The global phase 3 NETTER-1 trial is the most compelling evidence of clinical benefit for&#x000a0;<sup>177</sup>Lu-dotatate in midgut GINETs. In this study, 229 patients with inoperable, somatostatin-receptor-positive midgut NETs who experienced progressive disease on standard doses of long-acting octreotide were randomly assigned to 4 doses of&#x000a0;<sup>177</sup>Lu-dotatate every 8 weeks in 116 patients and long-acting octreotide&#x000a0;60 mg administered intramuscularly every 28 days in 113 patients.<xref ref-type="bibr" rid="article-140303.r14">[14]</xref>&#x000a0;In the&#x000a0;<sup>177</sup>Lu-dotatate group, patients continued receiving long-acting octreotide at 30 mg after each infusion of <sup>177</sup>Lu-dotatate and then monthly after completing all 4 treatments. The study met the primary endpoint of progression-free survival (PFS).&#x000a0;The estimated PFS rate at month 20 was significantly higher, with&#x000a0;<sup>177</sup>Lu-dotatate, at 65.2% versus 10.8%, which reached statistical significance. Among patients evaluated for radiographic response,&#x000a0;<sup>177</sup>Lu-dotatate showed a significantly higher objective response rate of 18% versus 3% compared to octreotide. The treatment-related serious adverse events (SAE) are more common, with&#x000a0;<sup>177</sup>Lu-dotatate at 9% versus 1%. The most common adverse event in the&#x000a0;<sup>177</sup>Lu-dotatate was nausea, possibly&#x000a0;due to the amino acid infusions administered during therapy for renal protection. <sup>177</sup>Lu-dotatate is associated with hematologic toxicities&#x000a0;due to irradiation of the bone marrow. The Netter-1 study reported mild degrees of thrombocytopenia in 25% of participants, lymphopenia in 18%, anemia in 14%, and leukopenia in 10% of participants that&#x000a0;occurred 4 to 6 weeks after each infusion and resolved within 8 weeks.<xref ref-type="bibr" rid="article-140303.r15">[15]</xref>&#x000a0;</p>
        <p>This treatment also has an impact on the quality of life. A study concluded that the time to deterioration in the quality of life was significantly longer with&#x000a0;<sup>177</sup>Lu-dotatate&#x000a0;compared with octreotide in several domains, including global health status, physical functioning, role functioning, fatigue, pain, diarrhea, disease-related worries, and body image. The differences were clinically significant in global health status, with a median time to deterioration in the quality of life of 28.8 months versus 6.1 months and physical functioning of 25.2 months versus 11.5 months.<xref ref-type="bibr" rid="article-140303.r16">[16]</xref>&#x000a0;In a later analysis, 5 years after the last patient, long-term outcomes were randomized with a median follow-up of 76 months in both groups.<xref ref-type="bibr" rid="article-140303.r17">[17]</xref>[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.uptodate.com/contents/metastatic-well-differentiated-gastrointestinal-neuroendocrine-carcinoid-tumors-systemic-therapy-options-to-control-tumor-growth/abstract/55">55</ext-link>] Notably, 12% of the 177 patients in the&#x000a0;<sup>177</sup>Lu-dotatate group received further PRRT, whereas&#x000a0;36% of patients in the control group had a crossover to <sup>177</sup>Lu-dotatate. The final overall survival (OS) in the intent-to-treat population was not significantly different between the study groups (HR 0.84, 95% CI 0.60 to 1.17), likely&#x000a0;due to crossover design.</p>
        <p>Myelodysplastic&#x000a0;syndrome (MDS) was reported with this treatment. Based on this data from the NETTER-1 trial, <sup>177</sup>Lu-dotatate was approved to treat somatostatin-receptor-positive gastroenteropancreatic NETs in adults. The recommended dosage is 7.4 GBq (200 mCi), with an intravenous infusion every 8 weeks for 4 doses.&#x000a0;There are no definitive selection criteria for <sup>177</sup>Lu-dotatate. The European Society guidelines&#x000a0;suggested <sup>177</sup>Lu-dotatate therapy in patients with an inoperable metastatic grade 1 and 2 well-differentiated NET with sufficient tumor uptake on diagnostic somatostatin receptor-based imaging and adequate renal and bone marrow reserve.<xref ref-type="bibr" rid="article-140303.r18">[18]</xref></p>
      </sec>
      <sec id="article-140303.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The most common adverse effect associated with <sup>177</sup>Lu-dotatate therapy is nausea with an incidence of up to 60%, associated with the amino acid infusions administered along with the treatment for renal protective effects. Beyond the administration day, the incidence of nausea is substantially lower. Hematological toxicities, including thrombocytopenia, lymphopenia, anemia, or leukopenia, were also reported with an incidence of approximately 10% to 25%, typically occurring 4 weeks after the infusions begin and lasting an average of 8 weeks.<xref ref-type="bibr" rid="article-140303.r15">[15]</xref>&#x000a0;</p>
        <p>Peptide receptor radioligand therapy (PRRT) has associated radiation risks that require close monitoring and counseling. Following each treatment, low radiation activity levels&#x000a0;occur due to the ongoing decay of radionucleotide disintegration. The day after treatments, the amount of radiation released is not harmful to surrounding individuals; however, this limited radiation could trigger alarms at international airports.<xref ref-type="bibr" rid="article-140303.r16">[16]</xref>&#x000a0;The most severe long-term toxicity associated with PRRT, with a median incidence of&#x000a0;0.5% to 2% 1 year after completion of PRRT, is therapy-related myeloid neoplasms (eg, myelodysplastic syndrome, acute leukemia, or myeloproliferative neoplasms).<xref ref-type="bibr" rid="article-140303.r19">[19]</xref><xref ref-type="bibr" rid="article-140303.r20">[20]</xref>&#x000a0;The definitive patient-related risk factors that could potentially place them at higher risk of developing therapy-related neoplasms are unknown. However, advanced age and bone metastasis are the potential risk factors that need further confirmation.<xref ref-type="bibr" rid="article-140303.r21">[21]</xref>&#x000a0;</p>
        <p>Therefore, the patients at high risk for developing myeloid neoplasms require close monitoring with complete blood counts for at least the first 2 years after <sup>177</sup>Lu-dotatate therapy. Renal dysfunction occurs in up to 20% of patients secondary to glomerular damage by radiation with PRRT.<xref ref-type="bibr" rid="article-140303.r22">[22]</xref>&#x000a0;There are no clear guidelines for continuing somatostatin analogs as maintenance post-PRRT. Fewer studies have indicated possible clinical benefits of combining PRRT with somatostatin analogs, preferably in patients with functional neuroendocrine tumors.<xref ref-type="bibr" rid="article-140303.r23">[23]</xref><xref ref-type="bibr" rid="article-140303.r24">[24]</xref>&#x000a0;The limitations of&#x000a0;<sup>177</sup>Lu-dotatate at present also include the complexity of administration. The <sup>177</sup>Lu-dotatate infusion is currently administered in the nuclear medicine department and needs thorough communication with medical oncology.</p>
      </sec>
      <sec id="article-140303.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>PRRT is associated with improved clinical outcomes, including overall and progression-free survival. PRRT is also related to improving clinical symptoms, quality of life parameters (eg, global health status, body image, and physical functioning), and other symptoms such as fatigue and diarrhea. The median time for quality of life deterioration is significantly higher with PRRT, with a difference of over 22 months.<xref ref-type="bibr" rid="article-140303.r16">[16]</xref>&#x000a0;</p>
        <p>A long-term retrospective study on 468 advanced NET patients who underwent at least 2 cycles of&#x000a0;<sup>177</sup>Lu-dotatate PRRT showed substantially improved quality of life and biochemical markers in most patients. With a median follow-up of 46 months, most patients achieved excellent disease control. The overall survival at 7 years was close to 80%.<xref ref-type="bibr" rid="article-140303.r25">[25]</xref>&#x000a0;<sup>177</sup>Lu-dotatate PRRT&#x000a0;was reported as a safe therapeutic option in heavily pretreated somatostatin receptor-positive bronchial NET patients with comparable efficacy and safety profile to other systemic treatment options. A retrospective analysis of 25 bronchial NET patients showed a median PFS of 17 months and an OS of&#x000a0;42 months.<xref ref-type="bibr" rid="article-140303.r26">[26]</xref></p>
      </sec>
      <sec id="article-140303.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are few limitations to <sup>177</sup>Lu-dotatate therapy. The treatment is quite expensive and complex in terms of administration. Ongoing clinical trials are still comparing&#x000a0;<sup>177</sup>Lu-dotatate therapy with other targeted systemic treatments. Also,&#x000a0;<sup>177</sup>Lu-dotatate therapy is currently only available at tertiary centers, limiting its widespread availability. The optimal selection of the candidates has been challenging.</p>
      </sec>
      <sec id="article-140303.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>A multidisciplinary team provides an integrated approach to treatment decisions to achieve the best clinical outcomes. Interventional radiology, medical oncology, and surgical oncology clinicians are critical stakeholders for individualized patient-centered treatment decisions. Randomized clinical trials with a head-to-head comparison with other treatment options, such as targeted therapies, are still being conducted; therefore, evidence of the optimal sequence of metastatic neuroendocrine tumor treatment is unavailable. Eligible patients are encouraged to enroll in open clinical trials.</p>
      </sec>
      <sec id="article-140303.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>PRRT involves&#x000a0;complex clinical and navigational patient needs and thorough interdepartmental communication for preparing a patient for each therapy. A nurse navigator is vital in providing a cohesive solution to address the multifaceted operational requirements associated with PRRT. The navigator offers critical ambulatory support to each patient throughout the treatment journey by delivering multidisciplinary coordination and patient education, monitoring treatment-related adverse effects, and following radiation safety protocols.</p>
      </sec>
      <sec id="article-140303.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team provides an integrated approach for treatment decisions in NET to achieve the best clinical outcomes. Given the newness of this agent, all clinicians, specialists, nurses, and pharmacists, particularly nuclear medicine specialty pharmacists, need to remain updated on the latest clinical trials and share findings with the rest of the team so that everyone may operate with the latest clinical knowledge.&#x000a0;Therapies such as <sup>177</sup>Lu-dotatate hold promise in treating this otherwise doleful diagnosis; therefore, patients should be encouraged to enter clinical trials to benefit themselves and future patients.</p>
      </sec>
      <sec id="article-140303.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140303&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140303">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140303/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140303">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140303.s11">
        <fig id="article-140303.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Post-lutetium therapy planar image of the whole body demonstrating multiple lesions in the osseous structures. Dawood Tafti, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Lutetium__therapy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140303.s12">
        <title>References</title>
        <ref id="article-140303.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duerr</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetics of neuroendocrine tumors.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">17382262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dasari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.</article-title>
            <source>JAMA Oncol</source>
            <year>2017</year>
            <month>Oct</month>
            <day>01</day>
            <volume>3</volume>
            <issue>10</issue>
            <fpage>1335</fpage>
            <page-range>1335-1342</page-range>
            <pub-id pub-id-type="pmid">28448665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnbeck</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Knigge</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Loft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berthelsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mortensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oturai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Elema</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kjaer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Head-to-Head Comparison of <sup>64</sup>Cu-DOTATATE and <sup>68</sup>Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.</article-title>
            <source>J Nucl Med</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>451</fpage>
            <page-range>451-457</page-range>
            <pub-id pub-id-type="pmid">27660147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>van Eijck</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>van Essen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kooij</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>van Aken</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>May</month>
            <day>01</day>
            <volume>26</volume>
            <issue>13</issue>
            <fpage>2124</fpage>
            <page-range>2124-30</page-range>
            <pub-id pub-id-type="pmid">18445841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imhof</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brunner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marincek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Briel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schindler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rasch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>M&#x000e4;cke</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Rochlitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Brand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>Jun</month>
            <day>10</day>
            <volume>29</volume>
            <issue>17</issue>
            <fpage>2416</fpage>
            <page-range>2416-23</page-range>
            <pub-id pub-id-type="pmid">21555692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ichikawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neuroendocrine tumor theranostics.</article-title>
            <source>Cancer Sci</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>1930</fpage>
            <page-range>1930-1938</page-range>
            <pub-id pub-id-type="pmid">35271754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>7</issue>
            <fpage>1813</fpage>
            <page-range>1813-1823</page-range>
            <pub-id pub-id-type="pmid">35633416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Assadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pirayesh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rekabpour</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Zohrabi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jafari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nabipour</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Esmaili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmadzadehfar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.</article-title>
            <source>Clin Nucl Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>978</fpage>
            <page-range>978-980</page-range>
            <pub-id pub-id-type="pmid">31689280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy.</article-title>
            <source>Clin Nucl Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>876</fpage>
            <page-range>876-878</page-range>
            <pub-id pub-id-type="pmid">31584494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesari Javan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aryana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Askari</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA: A Chance for 177Lu-DOTATATE Therapy?</article-title>
            <source>Clin Nucl Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>46</volume>
            <issue>9</issue>
            <fpage>e480</fpage>
            <page-range>e480-e482</page-range>
            <pub-id pub-id-type="pmid">34028407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hennrich</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kopka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Lutathera<sup>&#x000ae;</sup>: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2019</year>
            <month>Jul</month>
            <day>29</day>
            <volume>12</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">31362406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feijtel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doeswijk</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Verkaik</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Haeck</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chicco</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Angotti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Konijnenberg</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nonnekens</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.</article-title>
            <source>Theranostics</source>
            <year>2021</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>491</fpage>
            <page-range>491-505</page-range>
            <pub-id pub-id-type="pmid">33391488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uccelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Castello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Artioli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cittanti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marzola</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Florimonte</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Castellani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bissoli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Porto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Evangelista</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bartolomei</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lutathera<sup>&#x000ae;</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE.</article-title>
            <source>Pharmaceutics</source>
            <year>2023</year>
            <month>Mar</month>
            <day>31</day>
            <volume>15</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">37111596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strosberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>El-Haddad</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hendifar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chasen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mittra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Kulke</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jacene</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bushnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Dorisio</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lebtahi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hobday</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Delpassand</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srirajaskanthan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pavel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Seregni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lopera Sierra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thevenet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Erion</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>E</given-names>
              </name>
              <collab>NETTER-1 Trial Investigators</collab>
            </person-group>
            <article-title>Phase 3 Trial of <sup>177</sup>Lu-Dotatate for Midgut Neuroendocrine Tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Jan</month>
            <day>12</day>
            <volume>376</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-135</page-range>
            <pub-id pub-id-type="pmid">28076709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brabander</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van der Zwan</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Teunissen</surname>
                <given-names>JJM</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>BLR</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>van Eijck</surname>
                <given-names>CHJ</given-names>
              </name>
              <name>
                <surname>Franssen</surname>
                <given-names>GJH</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Efficacy, Survival, and Safety of [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.</article-title>
            <source>Clin Cancer Res</source>
            <year>2017</year>
            <month>Aug</month>
            <day>15</day>
            <volume>23</volume>
            <issue>16</issue>
            <fpage>4617</fpage>
            <page-range>4617-4624</page-range>
            <pub-id pub-id-type="pmid">28428192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strosberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chasen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kulke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bushnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hobday</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hendifar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sierra</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Thevenet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Margalet</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>E</given-names>
              </name>
              <collab>NETTER-1 Study Group</collab>
            </person-group>
            <article-title>Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>36</volume>
            <issue>25</issue>
            <fpage>2578</fpage>
            <page-range>2578-2584</page-range>
            <pub-id pub-id-type="pmid">29878866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Bodei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hendifar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mittra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pavel</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seregni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gericke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bartalotta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Demange</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mutevelic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <collab>NETTER-1 investigators</collab>
            </person-group>
            <article-title><sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high&#x02011;dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>1752</fpage>
            <page-range>1752-1763</page-range>
            <pub-id pub-id-type="pmid">34793718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hicks</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bodei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grozinsky-Glasberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borbath</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cwikla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>H&#x000f6;rsch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tiensuu Janson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramage</surname>
                <given-names>J</given-names>
              </name>
              <collab>Antibes Consensus Conference participants</collab>
            </person-group>
            <article-title>ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.</article-title>
            <source>Neuroendocrinology</source>
            <year>2017</year>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-309</page-range>
            <pub-id pub-id-type="pmid">28402980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergsma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Lom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Raaijmakers</surname>
                <given-names>MHGP</given-names>
              </name>
              <name>
                <surname>Konijnenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>BLBLR</given-names>
              </name>
              <name>
                <surname>Teunissen</surname>
                <given-names>JJM</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.</article-title>
            <source>J Nucl Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>452</fpage>
            <page-range>452-458</page-range>
            <pub-id pub-id-type="pmid">28775205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonbol</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Halfdanarson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Hilal</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.</article-title>
            <source>JAMA Oncol</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>6</volume>
            <issue>7</issue>
            <fpage>1086</fpage>
            <page-range>1086-1092</page-range>
            <pub-id pub-id-type="pmid">32297906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brieau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hentic</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lebtahi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palazzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ben Reguiga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rebours</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maire</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hammel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fenaux</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2016</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>L17</fpage>
            <page-range>L17-23</page-range>
            <pub-id pub-id-type="pmid">26932783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergsma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Konijnenberg</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>van der Zwan</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Teunissen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kooij</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Mauff</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>1802</fpage>
            <page-range>1802-11</page-range>
            <pub-id pub-id-type="pmid">27160225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yordanova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wicharz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brossart</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gonzalez-Carmona</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Strassburg</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Fimmers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Essler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmadzadehfar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.</article-title>
            <source>Clin Cancer Res</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>24</volume>
            <issue>19</issue>
            <fpage>4672</fpage>
            <page-range>4672-4679</page-range>
            <pub-id pub-id-type="pmid">29950352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Sundin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berruti</surname>
                <given-names>A</given-names>
              </name>
              <collab>ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org</collab>
            </person-group>
            <article-title>Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>844</fpage>
            <page-range>844-860</page-range>
            <pub-id pub-id-type="pmid">32272208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sitani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parghane</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Talole</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of indigenous <sup>177</sup>Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting.</article-title>
            <source>Br J Radiol</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>94</volume>
            <issue>1117</issue>
            <fpage>20201041</fpage>
            <pub-id pub-id-type="pmid">33095671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140303.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirvis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mandair</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gnanasegaran</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navalkissoor</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).</article-title>
            <source>Lung Cancer</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>150</volume>
            <fpage>70</fpage>
            <page-range>70-75</page-range>
            <pub-id pub-id-type="pmid">33075738</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
